Study results of CERAMENT|G, reported at the 2015 Orthopedic Research Society Annual Meeting, demonstrated that the Swedish product promoted new bone growth and decreased the rate of infection when compared to patients treated without a bone filler.
The manufacturer, headquartered in Lund, Sweden, is Bonesupport AB, a maker of injectable bone substitutes for use in orthopedic, trauma and bone infections.
“Treatment of chronic osteomyelitis often leaves a large critical defect which requires a bone void filler, yet current void fillers are inadequate because of donor site morbidity, expense or their propensity to encourage infection, ” said Mathias P.G. Bostrom, M.D., orthopedic surgeon at Hospital for Special Surgery in New York and co-author of the study. “This study showed CERAMENT|G to be effective in decreasing the rate of infection and simultaneously increasing new bone growth, two essential functions for successful management of osteomyelitis.”
Bonesupport officials describe Cerement|G as an injectable, bone graft substitute designed to fill bone gaps and voids and to augment hardware and bone fractures during surgical procedures. CERAMENT|G, they claim, has been shown to remodel into healthy native bone within 6 to 12 months.
“This is the first animal study to evaluate CERAMENT|G in a septic condition and we were very pleased with the results, ” said Bonesupport CEO Lloyd Diamond. Osteomyelitis, or bone infection, is reported to be a $1.7 billion annual cost where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are required to combat the problem.
